Published in final edited form as:

Exp Eye Res. 2014 November ; 128: 114–116. doi:10.1016/j.exer.2014.10.004.

Tissue Plasminogen Activator Reduces the Elevated Intraocular Pressure Induced by Prednisolone in Sheep

Oscar A. Candia, MD¹, Rosana M. Gerometta, MD², and John Danias, MD³

¹Department of Ophthalmology Mount Sinai School of Medicine, New York, NY, 10029, phone (212)241-6249, fax (212) 698-2000, oscar.candia@mssm.edu ²Departamento de Oftalmología, UNNE, Corrientes, Argentina ³Department of Ophthalmology, SUNY Downstate Medical Center and the SUNY Eye Institute, Brooklyn, NY 11203

We have previously shown that the tissue plasminogen activator (tPA) injected into the vitreous of sheep either reduced the prednisolone-elevated intraocular pressure (IOP) or prevented the IOP increase when injected simultaneously with the cortico-steroid (Gerometta et al., 2013). The effect was observed with injections of 100 µg to 1 mg and lasted for about 9 days. We reasoned that tPA was released from the vitreous and reached the trabecular meshwork (TM) where degraded the accumulated collagen. Thus, we decided to investigate if a single injection of tPA into the anterior chamber (AC) also reduced the IOP, and in what amount and time sequence. This would be important as an eventual treatment in which drops of tPA are instilled in the conjunctival sac.

Tissue plasminogen activator (tPA) is a serine protease that catalyzes the conversion of the inactive plasminogen into plasmin, the major degradative enzyme of blood clots via the proteolytic degradation of fibrin (Lijnen et al., 1995). This cascade can also lead to the activation of other pro-enzymes, including members of the matrix-metalloproteinase (MMP) family of enzymes, into their active forms (Matrisian, 1995; Murphy et al., 1992).

The MMPs directly degrade extracellular matrix (ECM) components, and these enzymes play a key role in the turnover and maintenance of the ECM of the TM, a process affecting outflow facility (Bradley et al., 1998; Keller et al., 2009).

tPA is expressed and secreted by various organ systems including the TM (Park et al., 1987; Shuman et al., 1988), and is found in the aqueous humor (Tripathi et al., 1988), suggesting that tPA could have an important role in regulating ECM composition in the TM. Glucocorticosteroids increase the accumulation of ECM components in the TM and decrease outflow facility, and have been shown to elicit reductions in tPA activity in TM organ and cell cultures (Seftor et al., 1994), suggesting a link between these phenomena. In past work, we demonstrated the effectiveness of glucocorticosteroids to induce ocular hypertension in

Corriedale sheep (Gerometta et al., 2009). The IOP of these animals increased over 2-fold within 1–2 weeks of topically applying either 0.5 or 1.0 % prednisolone acetate, three times daily. This IOP elevation occurred with a 100% incidence in the corticosteroid-treated eyes. Using prednisolone, the IOP of sheep will remain elevated as long as the instillation regimen is maintained.

All animal experiments were performed in accordance with the Association for Research in Vision and Ophthalmology (ARVO) guidelines. A total of 6 healthy female sheep (Corriedale breed) between 16 and 24 months of age, and weighing 35 to 40 kg, were selected from a local ranch in Corrientes, Argentina for this study. The eyes and general health of the animals were considered normal by an ophthalmologist and a veterinarian, respectively. Sheep were tagged for individual identification on their ear lobes and herded from pasture whenever it was necessary to 1) topically instill prednisolone, 2) inject either tPA or vehicle with arginine intracamerally, or 3) measure IOP by applanation tonometry. For each of these procedures, the sheep were guided into a funnel corral ending in a loose-fitting yoke. This arrangement allowed movement and holding of the head by one person while another either instilled the prednisolone, injected tPA into the AC under local anesthesia, or measured IOP with a hand-held Perkins tonometer calibrated for the sheep eye (Gerometta et al., 2009). Between all procedures, the animals were free to pasture.

Prednisolone Instillation

All sheep eyes received two drops of 1.0% prednisolone acetate ophthalmic suspension USP (manufactured by Alcon Laboratories, Inc. Fort Worth, Texas for Sandoz Inc. Princeton, NJ), 3-times daily (at 7 AM, 2 PM, and 7 PM) for the duration of the experiments. Such treatment induces a persistent ocular hypertension in sheep provided the instillation protocol is uninterrupted (Gerometta et al., 2009).

Lyophilized tPA was procured as Actilyse® from Boehringer Ingelheim SA (Buenos Aires, Argentina). 5 mg of Actilyse containing 4.8856 of arginine and 0.1155 mg of tPA was dissolved in 577.4 mL of sterile balanced saline solution (BSS). 50 µL of this solution containing 0.01 µg of tPA was injected into the AC of the 6 sheep under local anesthesia (2 drops of topical 0.5% proparacaine, Alcon Laboratorios Argentina S.A.). Lower amounts of tPA (0.0001 and 0.001 µg) were prepared by appropriate dilution and injected into the AC. An amount of arginine, equal to that present in the 3 tPA amounts used, was injected into the contralateral eye.

As previously indicated, bilateral topical treatment with prednisolone for 10 days doubled IOP on both eyes of the sheep. Subsequent intracameral injection of tPA had a dose-dependent effect. 0.0001 µg had no effect on IOP. 0.001 µg had a small decreasing effect on IOP in some eyes 5 hrs after injection that lasted 23 hrs.

0.01 µg reduced IOP in all eyes from a mean of 23.0 to 14.0 mm Hg 5 hrs after injection. The reduction lasted at least 24 hrs and 48 hrs later a small effect persisted. The fellow eye was injected with the same amount of arginine contained in the Actilyse. All eyes remained normal without sign of congestion or inflammation. These results are summarized in Fig 1 and Table 1.

The fibrinolytic system controls clotting of blood and subsequent dissolution of the thrombus. tPA activate plasminogen which then becomes plasmin that degrades fibrin (Lijnen et al., 1995). Many publications describe the use of human recombinant tPA either intracamerally for the acute management of excessive fibrin in the anterior segment of the eye (Wedrich et al., 1997; Wu et al., 2009; Erol et al., 2003; Ozveren et al., 2004). In those publications IOP reductions are mentioned but have been attributed to the dissolution of the fibrin clot in the anterior chamber. To date no experiments had been reported that use the fibrinolytic system in steroid-induced or open angle glaucoma. tPA has been used by intracameral injection at a dosage of 10–25 µg as a fibrinolytic in endophthalmitis and hyphema respectively (Wu et al., 2009; Kim et al., 1998). We found that amounts as low as 0.01 µg reduces IOP in only 4 hrs and the effect persists for at least 25 hrs. Possibly because of the low tPA/arginine dose that was injected in a volume of 50 µL into the AC, there were no signs of inflammation or toxicity. All eyes remained normal 2 weeks after completing the experiments. Although tPA has an effect on many enzymes, we posit that the reduction in IOP is due to its effect (direct or indirect) on the extracellular matrix of the TM. We realize that results of work on animal models may not necessarily indicate that similar mechanisms are operative in humans. Thus, they need to be confirmed with appropriate trials. Nevertheless, these findings could hold implications for the treatment of steroid-induced glaucoma and potentially in other open angle glaucoma.

Acknowledgements

This work was supported by National Eye Institute Grants EY00160, and EY20670, an unrestricted grant from Research to Prevent Blindness, Inc., New York, NY to the Department of Ophthalmology, Mount Sinai School of Medicine NY and a challenge grant from Research to Prevent Blindness, Inc., New York, NY to the Department of Ophthalmology, SUNY Downstate Medical School.

References

- Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. *Invest Ophthalmol Vis Sci*. 1998; 39:2649–2658. [PubMed: 9856774]
- Erol N, Ozer A, Topbas S, Yildirim N, Yurdakul S. Treatment of intracameral fibrinous membranes with tissue plasminogen activator. *Ophthalmic Surg Lasers Imaging*. 2003; 34:451–456. [PubMed: 14620747]
- Gerometta R, Podos SM, Danias J, Candia OA. Steroid-induced ocular hypertension in normal sheep. *Investigative ophthalmology & visual science*. 2009; 50:669–673. [PubMed: 18824726]
- Gerometta R, Kumar S, Shah S, Alvarez L, Candia O, Danias J. Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator. *Investigative ophthalmology & visual science*. 2013; 54:7903–7909. [PubMed: 24176900]
- Keller KE, Aga M, Bradley JM, Kelley MJ, Acott TS. Extracellular matrix turnover and outflow resistance. *Exp Eye Res*. 2009; 88:676–682. [PubMed: 19087875]
- Kim MH, Koo TH, Sah WJ, Chung SM. Treatment of total hyphema with relatively low-dose tissue plasminogen activator. *Ophthalmic Surg Lasers*. 1998; 29:762–766. [PubMed: 9760614]
- Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. *Baillieres Clin Haematol*. 1995; 8:277–290. [PubMed: 7549063]
- Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. *Trends Genet*. 1990; 6:121–125. [PubMed: 2132731]

- Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. *Ann N Y Acad Sci.* 1992; 667:1–12. [PubMed: 1339240]
- Ozveren F, Eltutar K. Therapeutic application of tissue plasminogen activator for fibrin reaction after cataract surgery. *J Cataract Refract Surg.* 2004; 30:1727–1731. [PubMed: 15313298]
- Park JK, Tripathi RC, Tripathi BJ, Barlow GH. Tissue plasminogen activator in the trabecular endothelium. *Invest Ophthalmol Vis Sci.* 1987; 28:1341–1345. [PubMed: 3112034]
- Seftor RE, Stamer WD, Seftor EA, Snyder RW. Dexamethasone decreases tissue plasminogen activator activity in trabecular meshwork organ and cell cultures. *J Glaucoma.* 1994; 3:323–328. [PubMed: 19920617]
- Shuman MA, Polansky JR, Merkel C, Alvarado JA. Tissue plasminogen activator in cultured human trabecular meshwork cells. Predominance of enzyme over plasminogen activator inhibitor. *Invest Ophthalmol Vis Sci.* 1988; 29:401–405. [PubMed: 3125123]
- Tripathi RC, Park JK, Tripathi BJ, Millard CB. Tissue plasminogen activator in human aqueous humor and its possible therapeutic significance. *Am J Ophthalmol.* 1988; 106:719–722. [PubMed: 3143267]
- Wedrich A, Menapace R, Ries E, Polzer I. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery. *Journal of Cataract & Refractive Surgery.* 1997; 23:873–877. [PubMed: 9292671]
- Wu TT, Wang HH. Intracameral recombinant tissue plasminogen activator for the treatment of severe fibrin reaction in endophthalmitis. *Eye (Lond).* 2009; 23:101–107. [PubMed: 17901882]

Fig. 1.

Representative experiment of the effect of 0.001 μ g of tPA when injected in the AC of the right eye. The AC of the left eye received arginine. There was a drastic reduction of the IOP of the right eye, which slowly recovered to the pre-tPA values despite the continued treatment with prednisolone. There was no effect of arginine on the IOP of the left eye.

Table 1

Values are expressed in mmHg.

Raw data of the tPA treated eye has a grey background.

The contralateral eye received arginine, which did not reduce IOP.